Document is current
Any future updates will be listed below
-
Authors
Vicino, Alex
Lauletta, Antonio
Bonanno, Silvia
Barbaccia, Adele
Valentino, Maria Lucia
Risi, Barbara
Torchia, Eleonora
Cheli, Marta
Tonin, Paola
Urbano, Guido
Saccani, Elena
Faedo, Elena
Ruggieri, Alessandra
Iannibelli, Eliana
Croce, Michele Giovanni
Zoppi, Dario
Costantini, Emanuele Maria
Rigamonti, Andrea
Colacicco, Giovanni
Grandis, Marina
Coccia, Michela
Barp, Andrea
Stephan, Aurélie Marroun
Carda, Stefano
Théaudin, Marie
Ravaglia, Sabrina
Ruggiero, Lucia
Mongini, Tiziana
Verriello, Lorenzo
Vattemi, Gaetano
Bortolani, Sara
Sansone, Valeria Ada
Filosto, Massimiliano
Previtali, Stefano Carlo
Liguori, Rocco
Rodolico, Carmelo
Garibaldi, Matteo
Maggi, Lorenzo https://orcid.org/0000-0002-0932-5173
-
Funding
Funding for this research was provided by:
Ministero della Salute
- License Information
-
More Information
Article History
Received: 8 September 2025
Revised: 31 October 2025
Accepted: 11 November 2025
First Online: 19 November 2025
Declarations
:
: LM has received honoraria for speaking, advisory boards, and compensation for congress participations from Sanofi, Roche, Biogen, Amicus Therapeutics, Alexion, Argenx, UCB, Johnson & Johnson, and Lupin, outside the submitted work. CHUV received for MT honoraria for speaking, advisory boards, and compensation for congress participations from Sanofi, Roche, Biogen, Alexion, Argenx, UCB, Johnson & Johnson, Alnylam, AstraZeneca, and Takeda, outside the submitted work. ES has received honoraria for speaking, advisory boards, and compensation for congress participation from Roche, Biogen, Alexion, Argenx, and UCB, not related to the submitted work. MC has received honoraria for speaking, advisory boards, and compensation for congress participation from Roche and Biogen. EMC has received honoraria for speaking, advisory boards, and compensation for congress participation from Roche and Biogen, not related to the submitted work.
: The study was conducted according to the Helsinki Declaration and its protocol was approved by the regional ethics committee “Lombardia 4” under the registered study number CET 17/24. Aggregated anonymized data were analyzed.
